South Korea will soon roll out a pilot project to use artificial intelligence, facial recognition and thousands of CCTV cameras to track the movement of people infected with the coronavirus, despite concerns about the invasion of privacy. Reuters reports: The nationally funded project in Bucheon, one of the country's most densely populated cities on the outskirts of Seoul, is due to become operational in January, a city official told Reuters. The system uses an AI algorithms and facial recognition technology to analyze footage gathered by more than 10,820 CCTV cameras and track an infected person's movements, anyone they had close contact with, and whether they were wearing a mask, according to a 110-page business plan from the city submitted to the Ministry of Science and ICT (Information and Communications Technology), and provided to Reuters by a parliamentary lawmaker critical of the project.

The Bucheon official said the system should reduce the strain on overworked tracing teams in a city with a population of more than 800,000 people, and help use the teams more efficiently and accurately. [...] The Ministry of Science and ICT said it has no current plans to expand the project to the national level. It said the purpose of the system was to digitize some of the manual labour that contact tracers currently have to carry out. The Bucheon system can simultaneously track up to ten people in five to ten minutes, cutting the time spent on manual work that takes around half an hour to one hour to trace one person, the plan said.

Long-time Slashdot reader fahrbot-bot quotes SciTechDaily: A discovery by researchers at the Texas A&M College of Medicine could lead to new therapies to prevent the virus from proliferating in the human body... The underlying mechanism of how SARS-CoV-2 escapes from the immune system has been poorly understood. However, researchers from the Texas A&M University College of Medicine and Hokkaido University have recently discovered a major mechanism that explains how SARS-CoV-2 can escape from the immune system and replicate in the human body. Their findings were recently published in the journal Nature Communications.

"We found that the SARS-CoV-2 virus carries a suppressive gene that acts to inhibit a human gene in the immune system that is essential for destroying infected cells," said Dr. Koichi Kobayashi, adjunct professor at the College of Medicine and lead author of the paper.

Naturally, the cells in a human's immune system are able to control virus infection by destroying infected cells so that the virus cannot be replicated. The gene that is essential in executing this process, called NLRC5, regulates major histocompatibility complex (MHC) class I genes, which are genes that create a pathway that is vital in providing antiviral immunity. Kobayashi and his colleagues discovered this in 2012.

"During infection, the amount and activity of NLRC5 gene become augmented in order to boost our ability of eradication of viruses," Kobayashi said. "We discovered that the reason why SARS-CoV-2 can replicate so easily is because the virus carries a suppressive gene, called ORF6, that acts to inhibit the function of NLRC5, thus inhibiting the MHC class I pathway as well."

New FDA-approved eye drops could replace reading glasses for millions: "It's definitely a life changer" "A newly approved eye drop hitting the market on Thursday could change the lives of millions of Americans with age-related blurred near vision, a condition affecting mostly people 40 and older," reports CBS News.

"Vuity, which was approved by the Food and Drug Administration in October, would potentially replace reading glasses for some of the 128 million Americans who have trouble seeing close-up." The new medicine takes effect in about 15 minutes, with one drop on each eye providing sharper vision for six to 10 hours, according to the company.... Vuity is the first FDA-approved eye drop to treat age-related blurry near vision, also known as presbyopia. The prescription drug utilizes the eye's natural ability to reduce its pupil size, said Dr. George Waring, the principal investigator for the trial.

"Reducing the pupil size expands the depth of field or the depth of focus, and that allows you to focus at different ranges naturally," he said.

A 30-day supply of the drug will cost about $80 and works best in people 40 to 55 years old, a Vuity spokesperson said. Side effects detected in the three-month trial included headaches and red eyes, the company said.

An Israeli study tracked more than 843,000 people who received two doses of the Pfizer vaccine — and then explored whether the results improved for the 758,000 who then also got a booster shot.

The results? HealthDay reports: Boosted folks are 90% less likely to die from a Delta infection than people relying solely on the initial two-dose vaccination, Israeli data show.

That protection will be critically important during the next couple of months as the Delta variant continues to dominate throughout the United States, said Dr. William Schaffner, medical director of the National Foundation for Infectious Diseases. "While we are preoccupied with Omicron, you need to remember that Delta is essentially in every town and city in the United States today — being transmitted, infecting new people, sending people to the hospital, in some parts of the country stressing the health care system once again," Schaffner said. "Although we have Omicron in the United States and it's starting to take hold, nonetheless well over 95% of all new infections today are caused by Delta...."

A second study out of Israel focused on infection and severity of illness, and it also produced good tidings for boosters in the face of the Delta variant. This study involved nearly 4.7 million Israelis who'd been fully vaccinated with Pfizer and were eligible for boosters. Confirmed infections were tenfold lower in the group of people who got the Pfizer booster, researchers reported. Further, results showed that the longer a booster was in a person's system, the more resistant they became to infection from the Delta strain.

The Food and Drug Administration authorized the first injectable monoclonal antibody cocktail for long-term prevention of Covid-19 among people with weakened immune systems before they have been exposed to the coronavirus. NBC News reports: The FDA issued an emergency use authorization Wednesday for AstraZeneca's antibody cocktail, Evusheld, for what is known as pre-exposure prophylaxis, or PrEP, against Covid-19. To date, such laboratory-produced antibodies have been authorized only as early treatment of Covid-19 or as preventive therapy for high-risk people immediately after close contact with someone who has tested positive.

Evusheld can be used as PrEP by people ages 12 and older who are moderately to severely immunocompromised and may not get adequate immune responses from a Covid vaccine. The therapy is also an option for the rare people who have histories of severe adverse reactions to a Covid vaccine or its components. The AstraZeneca therapy involves getting preventive injections as often as every six months. According to a large placebo-controlled clinical trial, the cocktail is about 83 percent effective at preventing symptomatic disease during such an interval. It's unclear how the highly mutated omicron variant of the coronavirus -- which is spreading in 57 countries, including the U.S. -- might affect the efficacy of the monoclonal antibody therapy.

fahrbot-bot shares a report from The New York Times: What if something in the blood of an athlete could boost the brainpower of someone who doesn't or can't exercise? Could a protein that gets amplified when people exercise help stave off symptoms of Alzheimer's and other memory disorders? That's the tantalizing prospect raised by a new study in which researchers injected sedentary mice with blood from mice that ran for miles on exercise wheels, and found that the sedentary mice then did better on tests of learning and memory. The study, published Wednesday in the journal Nature, also found that the type of brain inflammation involved in Alzheimer's and other neurological disorders was reduced in sedentary mice after they received their athletic counterparts' blood. Scientific results with mice don't necessarily translate to humans. Still, experts said the study supports a growing body of research.

The study involved mice that were about three months old -- roughly the equivalent of 25-to-30-year olds for humans. Some of the mice, nocturnal animals that love to run, could freely use exercise wheels in their cages and logged about four to six miles on the wheels each night. The wheels were locked for other mice that could scoot around their cages but could not get an extended cardio workout. [...] After 28 days, the researchers took a third group of mice that also did not exercise and injected them with blood plasma, the liquid that surrounds blood cells, from either the runner mice or the non-runner mice. Mice receiving runner blood did better on two tests of learning and memory than those receiving blood from the non-runner mice. In one test, which measures how long a mouse will freeze in fear when it is returned to a cage where it previously received an electric foot shock, mice with runner blood froze 25 percent longer, indicating they had better memory of the stressful event [...]. In the other test, mice with runner blood were twice as fast at finding a platform submerged in opaque water, he said. The team also found that the brains of mice with runner blood produced more of several types of brain cells, including those that generate new neurons in the hippocampus, a region involved in memory and spatial learning. A genetic analysis showed that about 1,950 genes had changed in response to the infusion of runner blood, becoming either more or less activated. Most of the 250 genes with the greatest activation changes were involved in inflammation and their changes suggested that brain inflammation was reduced.

Switzerland is giving the green light to so-called "suicide capsules" -- 3-D printed pods that allow people to choose the place where they want to die an assisted death. Global News reports: The country's medical review board announced the legalization of the Sarco Suicide Pods this week. They can be operated by the user from the inside. Dr. Philip Nitschke, the developer of the pods and founder of Exit International, a pro-euthanasia group, told SwissInfo.ch the machines can be "towed anywhere for the death" and one of the most positive features of the capsules is that they can be transported to an "idyllic outdoor setting."

Currently, assisted suicide in Switzerland means swallowing a capsule filled with a cocktail of controlled substances that puts the person into a deep coma before they die. But Sarco pods -- short for sarcophagus -- allow a person to control their death inside the pod by quickly reducing internal oxygen levels. The person intending to end their life is required to answer a set of pre-recorded questions, then press a button that floods the interior with nitrogen. The oxygen level inside is quickly reduced from 21 per cent to one per cent. After death, the pod can be used as a coffin. [...]

Nitschke said his method of death is painless, and the person will feel a little bit disoriented and/or euphoric before they lose consciousness. He said there are only two capsule prototypes in existence, but a third machine is being printed now, and he expects this method to become available to the Swiss public next year.

Pfizer and BioNTech said initial lab studies show a third dose of their Covid-19 vaccine neutralizes the omicron variant, results that will accelerate booster shot drives around the world. From a report: A booster with the current version of the vaccine increased antibodies 25-fold, providing a similar level as observed after two doses against the original virus and other variants, the companies said Wednesday. Blood plasma from people immunized with two doses of the vaccine has neutralizing antibody levels more than 25-fold less versus omicron than against the original strain of the virus, the companies said. "It's clear from these preliminary data that protection is improved with a third dose," Pfizer Chief Executive Officer Albert Bourla said in a statement. The initial data show a third dose could offer still offer enough protection from disease, BioNTech CEO Ugur Sahin said.

Scientists have raised concerns about a proposed overhaul of newborn screening that could lead to the UK becoming the first country to offer whole-genome sequencing for every baby. From a report: Speaking before the publication of plans for an NHS pilot study in which up to 200,000 babies' genomes will be sequenced and analysed, scientists suggested the initiative appeared designed to create a valuable health dataset rather than an effective method of improving the diagnosis of rare diseases. Anneke Lucassen, director of the Centre for Personalised Medicine at the University of Oxford, said that if the primary objective were improving newborn screening, there were alternative, more targeted tests that would be cheaper and potentially more reliable.

"If it was really all about [diagnosing more conditions], you could do that through other means," she said. "It's about helping to build the genomics industry in the UK and it's about creating a research resource so we can study people as they grow older." Lucassen said she was not opposed to the pilot, or even necessarily to these objectives, but wanted more transparency, "because otherwise it's sold as something that is not the full picture. The public needs to know that," she added. Sequencing the genomes of all newborns would represent a hugely ambitious upgrade to the routine "heel prick" test that all babies receive at about five days to detect nine serious health conditions including cystic fibrosis, sickle cell disease and various metabolic diseases.

fahrbot-bot shares a report from Gizmodo: New research this week finds that people hospitalized with severe covid-19 often pay a heavy price afterward. The study concluded that these survivors were more than twice as likely to die in the subsequent 12 months compared to people who had tested negative for the virus. This relatively increased risk of death was even higher for people under the age 65. While there remains much research to be done, studies thus far have made it clear that many covid-19 survivors can experience lingering symptoms even after the infection itself has cleared up. And those who are hospitalized are all the more vulnerable to these aftereffects. Severe covid often seriously damages the lungs and other organs, while life-saving interventions like steroids, ventilators, and life support devices like ECMO can take a toll on the body as well.

Researchers from the University of Florida had already published a study in July showing that hospitalized survivors were significantly more likely to be hospitalized again within six months, compared to those with mild to moderate covid-19. This new study of theirs, based on an examination of anonymous electronic health records, instead looked at the long-term mortality risk of patients up to a year later. Nearly 14,000 patients in the same health care system were studied. These included 178 diagnosed with severe COVID-19 and 246 diagnosed with mild to moderate covid-19, as well as many others who tested negative for the virus but may have been sick for other reasons and received medical care in some way. Compared to covid-negative patients, and even after accounting for other factors like age and sex, those with severe covid were 2.5 times more likely to die in the next 12 months after their illness. Overall, just over 52% of severe covid patients died in a year's time. There was no significant increased risk of mortality for mild to moderate cases, however. "About 20% of the deaths among these patients post-infection were attributed to problems with either the respiratory or cardiovascular system," the report adds. "[A]mong patients in this study, the associated risk of dying was actually relatively greater for survivors of severe covid under age 65 than it was for patients over 65. Compared to similarly aged but non-infected people, they were more than three times more likely to die in the months after their hospitalization."

The findings have been published in the journal Frontiers in Medicine.

The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic. From a report: "There is no world, I think, where (the effectiveness) is the same level... we had with Delta," Moderna Chief Executive Stephane Bancel told the Financial Times in an interview. "I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to are like 'this is not going to be good.'"

Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar. Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified. He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.

The US scientists who created the first living robots say the life forms, known as xenobots, can now reproduce -- and in a way not seen in plants and animals. CNN reports: Formed from the stem cells of the African clawed frog (Xenopus laevis) from which it takes its name, xenobots are less than a millimeter (0.04 inches) wide. The tiny blobs were first unveiled in 2020 after experiments showed that they could move, work together in groups and self-heal. Now the scientists that developed them at the University of Vermont, Tufts University and Harvard University's Wyss Institute for Biologically Inspired Engineering said they have discovered an entirely new form of biological reproduction different from any animal or plant known to science.

[T]hey found that the xenobots, which were initially sphere-shaped and made from around 3,000 cells, could replicate. But it happened rarely and only in specific circumstances. The xenobots used "kinetic replication" -- a process that is known to occur at the molecular level but has never been observed before at the scale of whole cells or organisms [...]. With the help of artificial intelligence, the researchers then tested billions of body shapes to make the xenobots more effective at this type of replication. The supercomputer came up with a C-shape that resembled Pac-Man, the 1980s video game. They found it was able to find tiny stem cells in a petri dish, gather hundreds of them inside its mouth, and a few days later the bundle of cells became new xenobots.

The xenobots are very early technology -- think of a 1940s computer -- and don't yet have any practical applications. However, this combination of molecular biology and artificial intelligence could potentially be used in a host of tasks in the body and the environment, according to the researchers. This may include things like collecting microplastics in the oceans, inspecting root systems and regenerative medicine. While the prospect of self-replicating biotechnology could spark concern, the researchers said that the living machines were entirely contained in a lab and easily extinguished, as they are biodegradable and regulated by ethics experts. "Most people think of robots as made of metals and ceramics but it's not so much what a robot is made from but what it does, which is act on its own on behalf of people," said Josh Bongard, a computer science professor and robotics expert at the University of Vermont and lead author of the study, writing in the Proceedings of the National Academy of Sciences. "In that way it's a robot but it's also clearly an organism made from genetically unmodified frog cell."

"The AI didn't program these machines in the way we usually think about writing code. It shaped and sculpted and came up with this Pac-Man shape," Bongard said. "The shape is, in essence, the program. The shape influences how the xenobots behave to amplify this incredibly surprising process."

The Los Angeles Times summarizes the results of a new medical study conducted by Northwestern University researchers on antibody levels protecting against Covid-19 in 974 people. "Those who were immunized against COVID-19 with two doses of an mRNA vaccine and received a booster shot about eight months later saw their levels of neutralizing antibodies skyrocket.

"Among this group of 33 fully vaccinated and boosted people, the median level of these antibodies was 23 times higher one week after the booster shot than it had been just before the tune-up dose." What's more, their median post-booster antibody level was three times higher than was typical for another group of people whose antibodies were measured a few weeks after getting their second dose of vaccine, when they're close to their peak.

And it was 53 times higher than that of a group of 76 unvaccinated people who had recovered from COVID-19 just two to six weeks earlier. Even compared to a group of 73 people who had weathered a bout with COVID-19 and went on to get two doses of an mRNA vaccine, the boosted group's median antibody level was 68% higher.

Study leader Alexis Demonbreun, a cell biologist at Northwestern University's Feinberg School of Medicine, said the data demonstrate that no matter how well protected a vaccinated person may think she is, getting a booster shot is likely to increase her neutralizing antibodies — and with it, her immunity — considerably. And because scientists expect large antibody responses to create more durable immunity, the protection afforded by the booster should last longer than the initial two-shot regimen did...

Among their other findings: After receiving two doses of vaccine, people who'd already had an asymptomatic infection were typically no better protected than vaccinated people who had never been infected.

Not a single scientist has applied to a UK government visa scheme for Nobel prize laureates and other award winners since its launch six months ago, New Scientist reported Tuesday. From a report: The scheme has come under criticism from scientists and has been described as "a joke." In May, the government launched a fast-track visa route for award-winners in the fields of science, engineering, the humanities and medicine who want to work in the UK. This prestigious prize route makes it easier for some academics to apply for a Global Talent visa -- it requires only one application, with no need to meet conditions such as a grant from the UK Research and Innovation funding body or a job offer at a UK organisation.

The number of prizes that qualify academics for this route currently stands at over 70, and includes the Turing Award, the L'Oreal-UNESCO for Women in Science International Awards, and various gongs awarded by professional or membership bodies both in the UK and elsewhere. "Winners of these awards have reached the pinnacle of their career and they have so much to offer the UK," said home secretary Priti Patel when the prestigious prize scheme launched in May. "This is exactly what our new point-based immigration system was designed for -- attracting the best and brightest based on the skills and talent they have, not where they've come from." But a freedom of information request by New Scientist has revealed that in the six months since the scheme was launched, no one working in science, engineering, the humanities or medicine has actually applied for a visa through this route.

An anonymous reader quotes a report from CNBC: Elon Musk on Wednesday said SpaceX is "hoping" to launch the first orbital flight test of its mammoth Starship rocket in January, a schedule that depends on testing and regulatory approval. "We'll do a bunch of tests in December and hopefully launch in January," Musk said, speaking at a meeting of the National Academies of Sciences, Engineering, and Medicine Space Studies Board.

The company's next major step in developing Starship is launching to orbit. First, the company needs a launch license from the Federal Aviation Administration for the mission, with the regulator expecting to complete a key environmental assessment by the end of this year. Musk noted that he wasn't sure if Starship would successfully reach orbit on the first try, but emphasized that he is "confident" that the rocket will get to space in 2022. "We intend to have a high flight rate next year," Musk said.

SpaceX aims to launch as many as a dozen Starship test flights next year, he said, to complete the "test flight program" and move to launching "real payloads in 2023." He stressed that creating a mass production line for Starship is crucial to the program's long-term goals, noting that the current "biggest constraint" on rocket manufacturing is how fast the company can build the Raptor engines needed for Starship. "I think, in order for life to become multiplanetary, we'll need maybe 1,000 ships or something like that," Musk said. "The overarching goal of SpaceX has been to advance space technology such that humanity can become a multi-planet species and, ultimately, a spacefaring civilization." SpaceX received a $2.9 billion contract from NASA to develop Starship for delivering astronauts to the moon's surface, but Musk said the company is "not assuming any international collaboration" or external funding for the rocket program. "[Starship] is at least 90% internally funded thus far," Musk said.

Drinking coffee or tea may be linked with a lower risk of stroke and dementia, according to the largest study of its kind. The Guardian reports: Strokes cause 10% of deaths globally, while dementia is one of the world's biggest health challenges -- 130 million are expected to be living with it by 2050. In the research, 365,000 people aged between 50 and 74 were followed for more than a decade. At the start the participants, who were involved in the UK Biobank study, self-reported how much coffee and tea they drank. Over the research period, 5,079 of them developed dementia and 10,053 went on to have at least one stroke.

Researchers found that people who drank two to three cups of coffee or three to five cups of tea a day, or a combination of four to six cups of coffee and tea, had the lowest risk of stroke or dementia. Those who drank two to three cups of coffee and two to three cups of tea daily had a 32% lower risk of stroke. These people had a 28% lower risk of dementia compared with those who did not drink tea or coffee. The research, by Yuan Zhang and colleagues from Tianjin Medical University, China, suggests drinking coffee alone or in combination with tea is also linked with lower risk of post-stroke dementia. "[W]hat generally happened is that the risk of stroke or dementia was lower in people who drank reasonably small amounts of coffee or tea compared to those who drank none at all, but that after a certain level of consumption, the risk started to increase again until it became higher than the risk to people who drank none," said professor Kevin McConway, an emeritus professor of applied statistics at the Open University who was not involved in the study.

"Once the coffee consumption got up to seven or eight cups a day, the stroke risk was greater than for people who drank no coffee, and quite a lot higher than for those who drank two or three cups a day."

The study has been published in the journal PLOS Medicine.

An anonymous reader quotes a report from The Verge: The Food and Drug Administration authorized a virtual reality system as a prescription treatment for chronic back pain, the agency announced today. The therapy, called EaseVRx, joins the short list of digital therapeutics cleared by the agency over the past few years. EaseVRx includes a VR headset and a device that amplifies the sound of the user's breath to assist in breathing exercises. It uses principles from cognitive behavior therapy, which aims to help people recognize and understand various thought patterns and emotions. The program addresses pain through relaxation, distraction, and improved awareness of internal signals, the FDA said in its statement.

The FDA authorized EaseVRx based on data from an eight-week study in 179 people with low back pain that had lasted six months or longer. Half used the EaseVRx program and half participated in another, two-dimensional virtual reality program that did not use cognitive behavioral therapy methods. Around two-thirds of participants using EaseVRx said they had more than 30 percent reduction in pain, while only 41 percent of the control group had a similar reduction. The reduced pain lasted for up to three months after the study for people in the EaseVRx group but not for the control group. The VR system could be an alternative option to opioid medications for back pain, Christopher Loftus, acting director of the Office of Neurological and Physical Medicine Devices at the FDA, said in a statement. [...] EaseVRx was developed by the company AppliedVR, which is also testing its platform as a treatment for fibromyalgia pain, burn pains, or pain during childbirth. The clearance for EaseVRx comes around a month after the FDA approved a VR treatment for children with the visual disorder amblyopia, or lazy eye.

Tonight 70 countries around the world set their clocks back an hour — including most of the United States, Canada, the EU and the UK.

Yet "The practice has drawn complaints about its disruptive effects on sleep and schedules," reports UPI, adding that "The American Academy of Medicine has called for an end to Daylight Saving Time, citing growing research that shows its deleterious effects on health and safety." [U.S.] Lawmakers are also increasingly wondering whether Daylight Saving Time is a good idea. At least 350 bills and resolutions have been introduced in every state taking aim at Daylight Saving Time since 2015, according to the National Conference of State Legislatures. Over the last four years, 19 states have passed similar legislation providing year-round daylight saving time if Congress allowed such changes.

Members of Congress have introduced legislation making changes to Daylight Saving Time, to no avail.

U.S. Sen. Sheldon Whitehouse, (Democrat — Rhode Island), said in a video posted to Twitter on Friday that the upcoming switchover was one of his least favorite times of the year since it means darker afternoons. He touted his Sunshine Protection Act that would make Daylight Saving Time permanent.

"We can do a lot better for daylight for everyone who is up in the afternoon," he said.
Also supporting that change is Florida Republican Senator Marco Rubio. "We're about to once again do this annual craziness of changing the clock, falling back, springing forward," Newsweek quotes him as saying. "Let's go to permanent daylight saving time. The overwhelming majority of members of Congress approve and support it. Let's get it done. Let's get it passed so that we never have to do this stupid change again."

But currently in America it's the Department of Transportation which is in charge of the practice, reports USA Today, and the Department believes that the practice saves energy, prevents traffic accidents and curbs crime.

So, as the Washington Post reports, "It's that time of the year again. We change the clocks back and we whine about it."

Brown University: At 89-years-old Manfred Steiner is finally what he always wanted to be: a physicist. On September 15, 2021, Steiner successfully defended his Ph.D. dissertation, "Corrections to the Geometrical Interpretation of Bosonization" in Brown University's Department of Physics with Professor Brad Marston serving as his adviser and Professors James Valles and Antal Jevicki serving as readers. "It's an old dream that starts in my childhood," says Steiner, "I always wanted to become a physicist." To say that Steiner's path to a Ph.D. in physics was not a traditional one would be an understatement. As a young man, Steiner fled the chaos of his birthplace of Vienna as World War II ended and eventually made his way to the United States. Steiner says, "I knew physics was my true passion by the time I graduated high school. But after the war, my uncle and my mother advised me to take up medicine because it would be a better choice in these turbulent after-war years."

Although he excelled at and loved physics, Steiner followed his family's advice. He says, "my uncle was a physician, an ear, nose and throat specialist, and he had taught in the United States for a while. He taught plastic surgery -- showing people how to make noses smaller or how to straighten them out. My family's advice was that medicine was the best path for me. So I reconciled myself, 'they are older and wiser,' and I followed their advice." Steiner went on to earn a medical doctorate in 1955 from the University of Vienna and soon after his graduation he made his way to Washington, D.C. where he finished his initial training in internal medicine. He next began a traineeship in hematology at Tufts University under Dr. William Damashek, who the American Society of Hematology describes as "the preeminent American clinical hematologist of his time." The traineeship included a three-year training in biology at the Massachusetts Institute of Technology and he earned a Ph.D. in biochemistry there in 1967.

"According to his bio on Harvard.edu, Mikao John was an erudite scholar: a medical student at the Harvard-MIT Program in Health Sciences and Technology who'd studied statistics and biochemistry at Yale and published research in the prestigious New England Journal of Medicine," reports Futurism: John was also a prolific author of blog posts on Harvard's site... But despite that veneer of academic authenticity, his posts didn't sound much like medical research. nstead, John's recent works carried titles like "KeefX.co: The Cannabis Fintech Company that Provides $1M in Funding a Month," which took the form of an extremely flattering article about a startup that provides financial services to weed businesses, and "Idahome Solar Makes Switching to Solar Power in Idaho a No-Brainer," which praised the "client-first mentality" and "incredible financing program" of a seemingly random solar panel company in Idaho.

As it turns out, there is no Harvard student by the name of Mikao John. Instead, a scammer invented that persona — and, alarmingly, managed to obtain the credentials to insert him into Harvard's web system — in order to sell SEO-friendly backlinks, and the prestige of being hyped up by someone at one of the world's most distinguished universities, to marketing firms with publicity-hungry clients.

The practice of scammers cooking up fake Harvard students to shill brands on the university's site appears to be widespread. In response to questions from Futurism, Harvard removed the Mikao John profile as well as about two dozen similar accounts being used for the same purpose... Swathes of Harvard.edu have become a spammer free-for-all where fake students and other accounts hawk an endless parade of dubious stuff: online casinos, synthetic urine, real estate in Florida, CBD, [42 more examples deleted] and many more incongruous yet trashy brands and services...

Overall, it felt as though if a reporter hadn't been sending numerous emails, the fake students probably would have been allowed to continue posting indefinitely.
Harvard eventually told the reporter that the scammers were signing up for their online classes, then using the email address they received to infiltrate the university's blogging platforms (writing fake posts about everything from bitcoin to concealed carry holsters and even bouncy castles.)

Ironically, Harvard's official motto (first adopted in 1643) is "Veritas" — the Latin word for truth.